A New Drug Slows Tumour Growth for More Than 50% of Patients – ICR
The Institute of Cancer Research shared a post on LinkedIn:
“NEWS: A new drug slows tumour growth when combined with low doses of radiotherapy.
Ceralasertib – a drug which blocks DNA damage repair – slowed tumour growth successfully with less than a third of the usual radiotherapy dose.
The Phase I PATRIOT Part C clinical trial, led by the ICR and The Royal Marsden NHS Foundation Trust, found that the drug stabilised tumour growth for more than half of patients and shrank the tumours of 35% of patients – with one patient’s tumour controlled for more than five years.
The combination of treatments also increased immune activity in some patients – changes which could leave them much more susceptible to immunotherapy.
Previous research by the same team found that the drug stabilises disease and increases immune activation when given alone. The researchers say the new combination could improve the success of radiotherapy and pave the way for more effective immunotherapy strategies, offering hope to patients whose cancers have previously resisted treatment.
Read the results of the trial, published in Nature Magazine Communications.”
Title:
Journal:
Authors:
More posts featuring ICR on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023